## IAP12 Rec'd PCT/PTO 03 JUL 2007

### PATENT ATTORNEY DOCKET NO. 50026/062001

Certificate of Mailing

Date of Deposit: July 3, 2007

Label Number: EV 920801265 US

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box-1450, Alexandria, VA 22313-1450,

Elvis De La Cruz

Printed name of person mailing correspondence

Signature of person mailing correspondence

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Katsuo SUEISHI et al.

Confirmation No.:

2391

Serial No.:

10/598,947

Art Unit:

1614

Filed:

September 15, 2006

Examiner:

Not Yet Assigned

Customer No.:

21559

Title:

METHODS FOR SUPPRESSING TUMOR PROLIFERATION

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# REPLY TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

In reply to the Notification to Comply with Requirements for Patent Applications
Containing Nucleotide and/or Amino Acid Sequence Disclosures that was mailed in
connection with the above-captioned application on May 24, 2007, applicants submit
herewith the following:

A substitute paper copy of the Sequence Listing;

An initial copy of the Sequence Listing in computer readable form;

A statement that the contents of the paper and computer readable forms of the Sequence Listing are the same as one another and contain no new matter; A Preliminary Amendment; and

A copy of the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, mailed on May 24, 2007.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

Respectfully submitted,

James D. DeCamp, Ph.D.

Reg. No. 43,580

JAN N. TITTER Ph.D. Plag. No. 52, 280





### United States Patent and Trademark Office

MY 9 9 ,

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alcoandria, Virginia 22313-1450 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATT	Y. DOCKET NO.	
10/598,947	Katsuo SUEISHI	500	50026/062001	
	INTERNATIONAL APPLICATION N		PLICATION NO.	
	_	PCT/JP05/04485		
21559	[	I.A. FILING DATE	PRIORITY DATE	
CLARK & FLBING LLP	_	03/15/2005	03/16/2004	

21559 CLARK & ELBING LLP 101 FEDERAL STREET BOSTON, MA 02110

CONFIRMATION NO. 2391 371 FORMALITIES LETTER

\*OC000000024017618\*

Date Mailed: 05/24/2007

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825 (d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821 (e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

	ACTION DUE REDUL / SEC	
For questions regarding compliance to 37 CFR 1.821-1.825 requirements, p	please somastate 7.3407	سك
	ESP //.24.07	
	INITIALS 700	

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. <a href="https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html">https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html</a>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <a href="http://www.uspto.gov/ebc.">http://www.uspto.gov/ebc.</a>

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

ANITA D JOHNSON

Telephone: (703) 308-9140 EXT 226

#### PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/598,947	PCT/JP05/04485	50026/062001

FORM PCT/DO/EO/922 (371 Formalities Notice)